The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto): GBG 69.
Christian Jackisch
No relevant relationships to disclose
Frank Wiebringhaus
No relevant relationships to disclose
Bettina Conrad
No relevant relationships to disclose
Michael Weigel
No relevant relationships to disclose
Bahriye Aktas
No relevant relationships to disclose
Harald Wagner
No relevant relationships to disclose
Kunibert Latos
No relevant relationships to disclose
Andreas Kohls
No relevant relationships to disclose
Ute Bueckner
No relevant relationships to disclose
Tanja Hauzenberger
No relevant relationships to disclose
Nikola Bangemann
No relevant relationships to disclose
John Hackmann
No relevant relationships to disclose
Michael R. Clemens
No relevant relationships to disclose
Bernhard Heinrich
No relevant relationships to disclose
Oliver Tome
No relevant relationships to disclose
Sibylle Loibl
No relevant relationships to disclose
Valentina Nekljudova
No relevant relationships to disclose
Gunter Von Minckwitz
No relevant relationships to disclose